| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Vaccines | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Vaccines | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Vaccines | Oncology |
Recent Updates
Recently added Catalysts
Neuphoria Therapeutics Inc.
$3.78
+0.02 (+0.4%)
D 33Pipeline Score Overvalued Pharma · Pre-Clinical
Market Cap
20.40 M
EPS
-7.90
P/E Ratio
-
Value Trade
59.81 K
0.4 %
Week
-4.43 %
1 Month
-15.92 %
3 Month
-12.62 %
6 Month
-97.92 %
5 Year
-97.92 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
707.00
52 Week Range
3.19 - 21.40
% held by Insiders
7.7 %
% held by Institutions
40.94 %
Enterprise Value
961.52 K
Total Shares
5.41 M
Short %
0.9 %
Float Shares
4.68 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neuphoria Therapeutics Inc.
162Total events
6Upcoming
34Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T1Acquisition
Subscribe to view catalyst details
Event history 2
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D33
Pipeline Score $1M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 43%
Micro Cap (rank 536 of 938)
Percentile RankNeuphoria Therapeutics Inc. faces pipeline headwinds (33/100), with $230M risk-adjusted pipeline value, led by BNC105P in Renal Cell Carcinoma (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BNC105P Small molecule | Renal Cell Carcinoma | Phase 1 | NCT01034631 | 10% | $127M | - | 154 | - | - | — | - | - |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BNC210 | Post-Traumatic Stress Disorder (PTSD) | Phase 2b | 2023-09-28 | total patients: 212; primary endpoint p value: 0.048; secondary endpoint depressive symptoms p value: 0.04; secondary endpoint sleep p value: 0.041; adverse events: headache >5%, nausea >5%, fatigue >5%, hepatic enzyme increase 14 (13.3%) patients treated with BNC210 vs 2 (0.19%) in the placebo group Read More | Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) ATTUNE trial met its primary endpoint showing BNC210 treatment led to Read More | |
BNC210 | Post-Traumatic Stress Disorder (PTSD) | Phase 2b | 2023-09-28 | total patients: 212; primary endpoint p value: 0.048; secondary endpoint depressive symptoms p value: 0.04; secondary endpoint sleep p value: 0.041; adverse events: headache >5%, nausea >5%, fatigue >5%, hepatic enzyme increase 14 (13.3%) patients treated with BNC210 vs 2 (0.19%) in the placebo group Read More | Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) ATTUNE trial met its primary endpoint showing BNC210 treatment led to Read More | |
BNC210 | Post-Traumatic Stress Disorder (PTSD) | Phase 2b | 2023-09-28 | total patients: 212; primary endpoint p value: 0.048; secondary endpoint depressive symptoms p value: 0.04; secondary endpoint sleep p value: 0.041; adverse events: headache >5%, nausea >5%, fatigue >5%, hepatic enzyme increase 14 (13.3%) patients treated with BNC210 vs 2 (0.19%) in the placebo group Read More | Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) ATTUNE trial met its primary endpoint showing BNC210 treatment led to Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NEUP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NEUP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NEUP▲ +17.7%on this news
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
Scancell and Neuphoria Therapeutics have announced an all-share merger, creating a combined entity that will operate under the Scancell name and seek a Nasdaq listing. The merger, which has been unanimously approved by both companies' boards, aims to advance Scancell's immunotherapy pipeline, particularly the lead program iSCIB1+. The transaction includes significant financing to support a Phase 3 trial for iSCIB1+ in advanced melanoma.
Read more →NEUPNeuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Neuphoria Therapeutics has confirmed ongoing discussions with Scancell Holdings plc regarding a potential collaboration. This engagement suggests a strategic move to enhance their development initiatives. The talks indicate a positive outlook for Neuphoria as it seeks to expand its operational capabilities.
Read more →NEUP▲ +6.3%on this news
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
Neuphoria Therapeutics Inc. has received a recommendation from Institutional Shareholders Services (ISS) for shareholders to vote for its director nominees on the WHITE proxy card. This recommendation comes amid a proxy contest initiated by Lynx1 Capital Management. Neuphoria's board is recognized for its proactive measures following the Phase 3 trial results of BNC210, which missed its endpoints, prompting a strategic review.
Read more →NEUPNeuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
Neuphoria Therapeutics has responded to Lynx1's revised interest in acquiring the company at a lower bid of $4.75 per share, which the board deems inadequate. The company is currently conducting a strategic review of alternatives for maximizing stockholder value and has received significant interest from various parties. Neuphoria's board emphasizes the importance of evaluating all proposals while ensuring that their own strategic processes are not overlooked. They encourage stockholders to support their existing board nominees amid the ongoing proxy contest with Lynx1.
Read more →NEUPNeuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
Neuphoria Therapeutics has released a statement addressing allegations made by Lynx1 Master Fund, which it claims are misleading and intended to distract shareholders. The company urges investors to support its board nominees while disputing Lynx1's criticisms regarding its strategic plans and board actions. Neuphoria asserts it has maintained transparency and has a robust strategic review process. The situation highlights an ongoing proxy contest where shareholder confidence is a significant concern.
Read more →NEUPNeuphoria Therapeutics Inc. Sends Letter to Stockholders
Neuphoria Therapeutics Inc. has issued a letter to its stockholders urging them to vote in favor of its two nominated board members at the upcoming 2025 Annual Meeting. The company is undergoing a strategic review aimed at maximizing value for all stockholders, particularly in light of its upcoming clinical trial data. Additionally, Neuphoria is raising capital to ensure financial stability, mitigating risks associated with clinical outcomes and potential takeover threats. The company expresses confidence in its nominated directors' ability to navigate this important phase effectively.
Read more →NEUPNeuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value
Neuphoria Therapeutics has initiated a strategic review to explore options for maximizing stockholder value, including potential mergers and acquisitions. The company has engaged H.C. Wainwright & Co. as its financial advisor. Additionally, Neuphoria received an unsolicited acquisition offer from Lynx1 Master Fund LP at $5.20 per share. The review comes after the company halted development of its lead drug candidate, BNC210, due to unmet clinical trial endpoints.
Read more →NEUPNeuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Neuphoria Therapeutics has adopted a limited-duration stockholder rights plan to safeguard the integrity of its strategic review process amid significant stock accumulation by certain investors. The plan aims to ensure fair participation for all stockholders and allows the Board time to make informed decisions. However, the company recently halted development of its lead drug candidate following a failed clinical trial.
Read more →NEUP▼ -68.5%on this news
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
Neuphoria Therapeutics announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder failed to meet its primary and secondary endpoints. As a result, the company will halt the development of its SAD program and conduct a strategic review of its operations. Neuphoria will also explore further development of BNC210 for PTSD.
Read more →NEUPNeuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
Neuphoria Therapeutics has achieved the last patient last visit milestone in its AFFIRM-1 Phase 3 trial for BNC-210, aimed at treating social anxiety disorder. The company reported a net loss of $0.4 million for the fiscal year ending June 30, 2025, a significant reduction from the previous year's loss. Neuphoria's cash position is expected to support operations through Q2 2027, with topline data from the trial anticipated in early Q4 2025.
Read more →NEUP▼ -8.3%on this news
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
Neuphoria Therapeutics has completed the target enrollment of 332 participants in its Phase 3 AFFIRM-1 trial for BNC-210, a treatment for social anxiety disorder (SAD). The trial is designed to evaluate the safety and efficacy of a single acute dose of BNC-210 compared to a placebo. The company anticipates that Phase 3 data will be available early in the fourth quarter of 2025. BNC-210 has received FDA Fast Track designation, which supports its development for SAD and other anxiety-related disorders.
Read more →NEUP▼ -7.2%on this newsshared move
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neuphoria Therapeutics Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Spyros Papapetropoulos will discuss the company's advancements in treatments for neuropsychiatric disorders, including their lead drug candidate BNC-210 for social anxiety disorder and PTSD. The presentation will be available on demand starting September 5.
Read more →NEUPNeuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
Neuphoria Therapeutics Inc. announced its upcoming presentation at the ASCP 2025 Annual Meeting. The company is focused on developing treatments for neuropsychiatric disorders, particularly its lead candidate BNC210 for social anxiety disorder and PTSD. Neuphoria also has a partnership with Merck for early-stage clinical trials targeting cognitive deficits in Alzheimer's disease.
Read more →NEUPNeuphoria Provides First Quarter 2025 Business Updates
Neuphoria Therapeutics has reported steady progress in its clinical pipeline for Q1 2025. The company is advancing its lead candidate, BNC210, in a Phase 3 study for Social Anxiety Disorder, with topline data anticipated in Q3. Additionally, its partnered asset MK-1167 is making strides in a Phase 2 trial for Alzheimer's disease.
Read more →NEUPNeuphoria Provides a Review of 2024 and Highlights 2025 Plans
Neuphoria Therapeutics Inc. reviewed its progress in 2024 and outlined its plans for 2025. The company reported that its BNC210 program for social anxiety disorder has entered Phase 3, while its collaboration with Merck for Alzheimer's treatment has moved to Phase 2. Neuphoria aims to enhance shareholder value by efficiently advancing its pipeline.
Read more →NEUP▼ -5.2%on this news
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
Neuphoria Therapeutics Inc. will ring the Nasdaq Opening Bell on March 3, 2025, to celebrate its redomiciliation to the US and the launch of the company. CEO Spyros Papapetropoulos emphasized the dedication of the team in positioning Neuphoria for long-term success. The event will be broadcast live from Times Square, New York City.
Read more →NEUPNeuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
Neuphoria Therapeutics Inc. announced it will receive a $15 million milestone payment from Merck due to the initiation of a Phase 2 clinical trial for MK-1167, aimed at treating Alzheimer's disease symptoms. This payment marks the second milestone achieved in Neuphoria's collaboration with Merck, who has the potential to provide up to $450 million in future milestone payments. Neuphoria's drug pipeline includes various candidates targeting neuropsychiatric disorders, further emphasizing its commitment to developing impactful treatments.
Read more →NEUPDESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Neuphoria Therapeutics Inc., a Delaware corporation (the "Company") is a summary only. This summary is subject to the General Corporation Law
Neuphoria Therapeutics Inc. has outlined details regarding its capital stock under Delaware law. The company is authorized to issue a significant number of common and preferred shares and has specific provisions regarding voting rights, dividends, and liquidation rights. Additionally, the certificate of incorporation includes various measures that may hinder stockholder influence over board composition and corporate control, potentially complicating takeover attempts.
Read more →NEUPNeuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
Neuphoria Therapeutics Inc. has completed its re-domiciliation from Australia to the United States, establishing itself as the ultimate parent company of Bionomics Limited. Trading of its common stock under the ticker symbol 'NEUP' on the Nasdaq is set to commence on December 24, 2024. Additionally, Neuphoria will issue stock options and warrants to existing holders of Bionomics securities. This strategic move is aimed at enhancing its operations in the US market and advancing its therapeutic candidates.
Read more →NEUPSupreme Court of New South Wales approves Bionomics' re-domiciliation Adelaide, Australia and Cambridge, Mass.
Bionomics Limited has received approval from the Supreme Court of New South Wales for its re-domiciliation from Australia to the United States. This change will result in Neuphoria Therapeutics Inc. becoming the ultimate parent company of Bionomics. The implementation date for this Scheme is set for December 23, 2024, with Neuphoria shares poised to trade on Nasdaq under the symbol 'NEUP' starting December 24, 2024. This transition marks a significant shift for the company as it seeks to enhance its operations in the U.S. market.
Read more →NEUPScheme Implementation Agreement - Amending Agreement Date : 24 October 2024 Parties Bionomics Name Bionomics Limited (a company incorporated in South Australia) ACN 075 582 740 Address 200 Greenhill Road, Eastwood SA 506
Bionomics Limited and Neuphoria Therapeutics Inc. have amended their Scheme Implementation Agreement dated October 1, 2024. The amendments detailed in the document take effect immediately and clarify various aspects including the roles of ADS and shareholders. This agreement aims to facilitate the transfer of Bionomics shares to Neuphoria under the specified arrangement conditions. Key provisions emphasize the operational and legal framework for this corporate action.
Read more →NEUPBionomics Limited announces intention to re-domicile to the United States Adelaide, Australia and Cambridge, Mass.
Bionomics Limited announced its intention to re-domicile from Australia to the United States, which is subject to shareholder and regulatory approval. This move aims to reduce compliance costs associated with Australian regulations and enhance visibility among international investors. Should the scheme proceed, all existing shareholders will receive shares in a new parent company, Neuphoria Therapeutics Inc., which will be listed on Nasdaq. The re-domiciliation is expected to be tax-neutral and not to affect the company's assets or management structure significantly.
Read more →NEUPSECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is made and entered into as of
Bionomics Limited has entered into a Securities Purchase Agreement with several investors on May 31, 2024, highlighting their intention to sell restricted American Depositary Shares (ADSs) along with accompanying warrants. These ADSs will represent 180 ordinary shares each, and a registration rights agreement will be executed to facilitate compliance with securities laws. This move indicates investor confidence and aims to enhance the company's funding capabilities but does not detail any financial terms or implications of the agreement.
Read more →NEUPSigned in accordance with a resolution of the directors made pursuant to section 306(3) of the Corporations Act 2001 . On behalf of the directors Spyridon “Spyros” Papapetropoulos President, Chief Executive
Bionomics Limited has released its Half-Year Report for the period ending December 31, 2023. The report highlights a decrease in cash reserves and an operating loss after tax, although Bionomics has shown progress in its clinical trials, particularly for the drug candidate BNC210. Following a favorable End-of-Phase 2 meeting with the FDA, the company plans to initiate a Phase 3 study for BNC210, pending funding. The report details the company's financial situation and outlines the principal activities and future plans regarding its CNS-focused drug pipeline.
Read more →NEUPResults of Annual General Meeting ADELAIDE, Australia, and
Bionomics Limited announced the results of its Annual General Meeting held on November 30, 2023, in Adelaide, Australia. The meeting confirmed the re-election of Mr. Aaron Weaver and Dr. Jane Ryan as directors, with both receiving over 99% support from shareholders. Notably, one resolution regarding the re-election of Dr. Errol De Souza was withdrawn. The company continues to focus on developing its lead drug candidate and other CNS treatment options.
Read more →NEUPBionomics Announces Retirement of Board Member ADELAIDE, Australia, and
Bionomics Limited has announced that Dr. Errol De Souza will retire from its Board of Directors at the upcoming Annual General Meeting on November 30, 2023. The company expresses gratitude for his extensive contributions over his 15-year tenure. Following his departure, the Board will consist of six members. Bionomics continues to advance its lead asset, BNC210, into Phase 3 trials for social anxiety disorder and is preparing for further discussions with the FDA regarding its development in post-traumatic stress disorder.
Read more →NEUPBIONOMICS LIMITED ACN 075 582 740 Notice of Annual General Meeting Explanatory Statement and Proxy Form Date of Meeting: Thursday, 30 November 2023 Time of Meeting: 9.30am (Adelaide Time, ACDT) This meeting will be held
Bionomics Limited will hold its Annual General Meeting (AGM) on Thursday, 30 November 2023, at 9:30 am (ACDT). The meeting will occur virtually, allowing shareholders to participate online. Shareholders are encouraged to lodge their proxy forms prior to the meeting, which can be accessed electronically via the company's website. The Notice of Meeting includes several resolutions for consideration, including the re-election of a director.
Read more →NEUPBionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder • Positive outcome of End-of-Phase 2 meeting wit
Bionomics Limited announced a successful End-of-Phase 2 meeting with the FDA regarding its lead candidate BNC210 for the treatment of Social Anxiety Disorder. The meeting confirmed alignment with the FDA on the Phase 3 clinical program and essential nonclinical studies required for registration. Bionomics plans to begin Phase 3 trials in Q1 2024, aiming to provide a novel treatment option for millions of Americans suffering from this mental health condition.
Read more →NEUPBionomics Limited ABN 55 075 582 740 Statutory Accounts Director's Report In accordance with the Corporations Act 2001, the directors of Bionomics Limited ( Bionomics or “Company”) report on the Company and
Bionomics Limited reported its statutory accounts for the financial year ending June 30, 2023. The company has been focusing on developing novel drug candidates for CNS disorders, particularly for social anxiety disorder and PTSD. Despite a notable increase in operational losses, Bionomics successfully completed its Phase 2 PREVAIL Study for BNC210 and is preparing for a Phase 3 study, contingent on securing funding. The operating results point to challenges with cash flow and rising costs as the company navigates its drug development pipeline.
Read more →NEUPBionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) ATTUNE trial met its primary endpoint showing BNC210 treatment led to
Bionomics announced positive topline results from its Phase 2b ATTUNE trial of BNC210 for treating PTSD, successfully meeting its primary endpoint with statistically significant symptom reduction. The trial involved 212 patients and showed notable improvements in depressive symptoms and sleep among secondary endpoints. BNC210's safety profile was deemed favorable, though some participants reported elevated hepatic enzymes. Bionomics plans to engage with the FDA regarding the drug's potential registration pathway.
Read more →NEUPFactors Affecting Future Performance This announcement contains “forward-looking” statements within the meaning of the U.S. federal securities laws. Any statements contained in this announcement that relate
Bionomics Limited has reported on its quarterly cash flow and activities, highlighting major advancements in its clinical trials for BNC210, aimed at treating PTSD and Social Anxiety Disorder. The company has completed target enrolment for its Phase 2b ATTUNE clinical trial, with results expected this September. Additionally, Bionomics is preparing for an FDA End of Phase 2 meeting, which may pave the way for a Phase 3 study in Social Anxiety Disorder set for early 2024. However, the company has noted a decline in cash reserves, raising concerns about its financial stability.
Read more →NEUPASX ANNOUNCEMENT 28 July 2023 Shareholder communication on the De-listing process Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical
Bionomics Limited has communicated to shareholders regarding its upcoming voluntary de-listing from the ASX. This process follows a previous announcement and includes information about options available to shareholders, as well as an ADS Conversion Facility Election Form. Despite this, Bionomics is continuing its development of therapeutics for serious central nervous system disorders, including its lead candidate BNC210, and maintains a partnership with Merck & Co. for further advancements in the pipeline.
Read more →NEUPFOR FURTHER INFORMATION PLEASE CONTACT: Baker Young GPO Box 1672 Adelaide, South Australia 5001 Australia +61 8 8236 8899 (Monday – Friday 9:00am – 5:00pm (ACST)) Bionomics@bakeryoung.com.au About Bionomics
Bionomics Limited has announced its intention to voluntarily delist from the Australian Securities Exchange (ASX) in favor of maintaining its listing solely on Nasdaq. The decision stems from a review of the costs and administrative burdens associated with dual listing, as well as a desire to better leverage fundraising opportunities in the U.S. The delisting process is underway, with the company set to notify its shareholders of the specific timing and implications of this move.
Read more →NEUPJuly 2023 Lisa Banh Senior Advisor, Listings Compliance ASX Compliance Pty Limited 20 Bridge Street, Sydney, NSW 2000 By email only Dear Lisa, REQUEST FOR TRADING HALT Bionomics Limited (ASX:BNO) ( Bionomics or Company )
Bionomics Limited has requested an immediate halt to trading of its securities on the ASX due to an application for removal from the Official List. The trading halt will be effective until July 25, 2023, or until the company makes a formal announcement regarding this matter. The firm has stated that it does not anticipate any issues with the halt being granted.
Read more →NEUPNotification of cessation of +securities Part 3 - Issued capital following changes Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise: 3.1 Quoted +
On July 7, 2023, BNO announced the cessation of several securities, impacting its issued capital structure. This cessation includes the expiration of options and the lapse of conditional rights to securities for key management personnel. Following these adjustments, the total number of ordinary fully paid shares and other unquoted equity securities is detailed in the announcement, reflecting the current state of the entity’s issued capital. No consideration is being paid for the cessation of these securities.
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 28 April 2023 Quarterly Activities and Cashflow Report Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing nove
Bionomics Limited has released its quarterly activities and cashflow report for the period ending March 31, 2023. The company highlighted key leadership changes, including Dr. Errol B. De Souza becoming Non-Executive Chairman and Dr. Spyridon Spyros Papapetropoulos taking on the role of CEO. The report also details progress in clinical trials for BNC210, including the completion of enrollment in a Phase 2b study for PTSD and the preparation for an FDA End of Phase 2 Meeting regarding its SAD program. Despite a decrease in cash reserves, Bionomics maintains sufficient funds for ongoing operations until mid-2024.
Read more →NEUPNew and Recent Appointee Bios Mr. Fisher is an experienced corporate advisor and public company director, with a proven track record for implementing strategies that enhance shareholder value. His main areas of expertise
Bionomics Limited has announced significant leadership changes aimed at enhancing its U.S.-focused strategy and advancing growth. Alan Fisher has been appointed as the Chair of the Board of Directors, succeeding Errol De Souza, who remains with the company as a Non-Executive Director. Tim Cunningham joins as Chief Financial Officer, and additional appointments include Julie Kerner and Atul R. Mahableshwarkar, further emphasizing the expansion of the leadership team. These strategic updates reflect Bionomics' commitment to drive sustainable growth and enhance its late-stage product candidates.
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 27 April 2023 BIONOMICS ANNOUNCES THE COMPLETION OF ENROLMENT IN PHASE 2B ATTUNE CLINICAL TRIAL OF BNC210 IN PATIENTS WITH POST-TRAUMATIC STRESS DISORDER (PTSD) Topline results expecte
Bionomics Limited has announced the completion of participant enrolment in its Phase 2b ATTUNE clinical trial for BNC210, aimed at treating Post-Traumatic Stress Disorder (PTSD). Approximately 200 participants have been enrolled across 27 sites in the U.S. and 7 sites in the U.K. Topline results are anticipated in Q3 2023, which may pave the way for further development of BNC210 in addressing serious CNS disorders. The completion of this trial marks a significant milestone for Bionomics as it seeks to enhance therapeutic options for PTSD and other anxiety-related conditions.
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 9 March 2023 Bionomics Reports Promising Update on Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD) • Both doses of BNC210 as an acute treatment resul
Bionomics announced promising results from its Phase 2 PREVAIL study of BNC210 for the treatment of Social Anxiety Disorder (SAD). Both tested doses of the drug significantly reduced anxiety during public speaking tasks, achieving statistical significance in various analyses. The overall safety profile remains favorable, with BNC210 showing characteristics of a fast-acting non-sedating anxiolytic. The company plans to discuss these findings in an upcoming End of Phase 2 meeting, signaling confidence in the drug's late-stage development.
Read more →NEUPAppendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
Bionomics Limited has submitted a Change of Director's Interest Notice for Dr. Errol De Souza, detailing changes in the director's interests in securities. As of February 23, 2023, Dr. De Souza acquired 10,000,000 unlisted options and disposed of 1,666,667 unlisted options. The notice includes the number of securities held before and after the changes. This submission follows ASX listing rule 3.19A.2, which requires disclosure of changes in a director's interests in a timely manner.
Read more →NEUPABN 53 075 582 740 BIONOMICS LIMITED ASX half-year information – 31 December 2022 Lodged with the ASX under Listing Rule 4.2A Contents Page Results for Announcement to the Market 2 Announcement 3 Half-year Report
Bionomics Limited reported its half-year results for FY2023, indicating an increased net loss and decreased cash reserves compared to the previous year. Despite challenges, including missing a primary endpoint in the PREVAIL Study for Social Anxiety Disorder, the company noted progress in pipeline development and ongoing partnerships. Additionally, Bionomics is advancing its research in Alzheimer's disease with Merck & Co. and has upcoming topline results expected for the ATTUNE study in mid-2023. The leadership team has also seen a change with the appointment of a new CEO.
Read more →NEUPABN 53 075 582 740 21 February 2023 ASX Market Announcements ASX Limited Level 4 Stock Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam, RESULTS OF ANNUAL GENERAL MEETING In accordance with Listing Rule 3.
Bionomics Limited held its Annual General Meeting on February 21, 2023, where several resolutions were put to vote. The results indicated strong support for all proposed resolutions, including the issuance of options to company executives and the ratification of prior share issues. This positive outcome reflects shareholder confidence in the company's strategic direction and its development of novel treatments for CNS disorders.
Read more →NEUPAbout Bionomics Limited Bionomics Limited (ASX: BNO, Nasdaq: BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering f
Bionomics Limited, a clinical-stage biopharmaceutical company, reported updates in its quarterly activities and cashflow. The company continues to develop BNC210 for Social Anxiety Disorder but did not meet its primary endpoint in recent clinical trials. Appointments of new executives and ongoing studies indicate a commitment to further analysis and future developments. Additionally, financial stability appears to be secured with an adequate cash runway for continued operations.
Read more →NEUPEXPLANATORY STATEMENT Purpose of Information This Explanatory Statement ( Explanatory Statement ) accompanies and forms part of the Company's Notice of General Meeting ( Notice ) for the General Meeting ( Meeting ) will
Bionomics Limited has announced a General Meeting for its shareholders, scheduled for February 21, 2023. The meeting will be held virtually, allowing shareholders to participate through an online platform. Shareholders are encouraged to submit their proxies electronically or attend online. New legislative changes will allow for communications to be received electronically, but physical documents will only be mailed upon request, highlighting a shift towards digital engagement.
Read more →NEUPRule 3.19A.1 Appendix 3X Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be ma
Bionomics Limited has submitted an Initial Director's Interest Notice to the ASX regarding the interests of director Spyridon Papapetropoulos, who was appointed on January 5, 2023. This notice complies with listing rule 3.19A.1, highlighting the requirement for any relevant information or documents to be submitted promptly. It includes stipulations about the ownership and disclosure of securities managed by the director, though specific details on interests or contracts were not provided.
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 19 December 2022 Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder • BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder -BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint -Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endp
Read more →NEUPABN 53 075 582 740 16 November 2022 ASX Market Announcements ASX Limited Level 4 Stock Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam, RESULTS OF ANNUAL GENERAL MEETING In accordance with Listing Rule 3.
ASX Market Announcements ASX Limited Stock Exchange Centre 20 Bridge Street RESULTS OF ANNUAL GENERAL MEETING In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the attached document provides details of the proxies received and the manner in whic
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 25 October 2022 Quarterly Activities and Cashflow Report Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing no
Quarterly Activities and Cashflow Report Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious centr
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 18 October 2022 Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million Bionomics Limited (ASX: BNO, NASDAQ: BNOX), a clinical stage biopharmaceutical company, is pleas
Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million Bionomics Limited (ASX: BNO, NASDAQ: BNOX), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$4,634,307.30 research and development (R&D) tax incentive refund
Read more →NEUPBIONOMICS LIMITED ACN 075 582 740 Notice of Annual General Meeting Explanatory Statement and Proxy Form Date of Meeting: Wednesday, 16 November 2022 Time of Meeting: 9.30am (Adelaide Time, ACDT) Place of Meeting: Banquet
Notice of Annual General Meeting Explanatory Statement and Proxy Form Wednesday, 16 November 2022 9.30am (Adelaide Time, ACDT) Adelaide Festival Centre, Bionomics Limited Notice of Annual General Meeting 1 NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given that the Ann
Read more →NEUPBIONOMICS ANNUAL REPORT Director's Report CONTENTS PAGE EXECUTIVE CHAIRMAN REPORT 1 DIRECTORS' REPORT 2 ANNUAL CONSOLIDATED FINANCIAL STATEMENTS 23 INDEPENDENT AUDIT REPORT 71 SHAREHOLDERS INFORMATION 76 2 Executive Chai
2022 BIONOMICS ANNUAL REPORT PAGE EXECUTIVE CHAIRMAN REPORT 1 DIRECTORS' REPORT 2 ANNUAL CONSOLIDATED FINANCIAL STATEMENTS 23 INDEPENDENT AUDIT REPORT 71 SHAREHOLDERS INFORMATION 76 Executive Chairman's Report This past year has been one of monumental progress for Biono
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 4 October 2022 Bionomics to Participate in the Cantor Neurology & Psychiatry Conference Bionomics Limited (ASX: BNO, NASDAQ:BNOX), ( Bionomics or Company ), a clinical-stage biopharmac
Bionomics to Participate in the Cantor Neurology & Psychiatry Conference Bionomics Limited (ASX: BNO, NASDAQ:BNOX), (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients
Read more →NEUPDr. Charlie Taylor is an Associate Professor of Psychiatry at UC San Diego. He received his PhD in Clinical Psychology from the University of British Columbia (Canada) and has over 20 years of experience in the assessmen
Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder Bionomics Limited (ASX: BNO, NASDAQ:BNOX), (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to announce that it will host a Key Opinion Leader (KOL) webinar on BNC210, a proprietary
Read more →NEUPReleased on authority of the Board. FOR FURTHER INFORMATION PLEASE CONTACT: General: Ms Suzanne Irwin Company Secretary +61 8 8150 7400 CoSec@bionomics.com.au Investor Relations: Mr. Connor Bernstein Vice President, Stra
Bionomics reports Full Year Financial Results Bionomics Limited (ASX:BNO, OTCQB:BNOEF), today announced its financial results for the 12 months ended 30 June 2022. Bionomics is a clinical stage biopharmaceutical company developing novel, allosteric, ion channel modulators desig
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 8 August 2022 Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M Bionomics Limited (ASX: BNO, NASDAQ:BNOX), a clinical stage biopharmaceutical company, is pleased to anno
Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M Bionomics Limited (ASX: BNO, NASDAQ:BNOX), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$2,085,453.17 research and development (R&D) tax incentive refund relatin
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 29 July 2022 Quarterly Activities and Cashflow Report Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a global, clinical stage biopharmaceutical company, today r
Quarterly Activities and Cashflow Report Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a global, clinical stage biopharmaceutical company, today released its Appendix 4C Quarterly Cashflow Report. Highlights during the Quarter ended 30 June 2022 (Quarter
Read more →NEUPNotification of Issue, Conversion or Payment up of Unquoted Equity Securities Part 5 - Other Listing Rule requirements 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did no
Announcement Summary Date of this announcement Wednesday July 20, 2022 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transf
Read more →NEUPABN 53 075 582 740 13 June 2022 Bionomics Investor Webinar Bionomics Limited (ASX: BNO |Nasdaq: BNOX ), ( Bionomics or the Company ), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel mo
Bionomics Investor Webinar Bionomics Limited (ASX: BNO |Nasdaq: BNOX ), (Bionomics or the Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous s
Read more →NEUPRule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be
Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Bionomics Ltd ABN
Read more →NEUPBionomics Limited to Participate in Upcoming Investor Conferences
Bionomics Limited to Participate in Upcoming Investor Conferences ADELAIDE, Australia, May 16, 2022 /PRNewswire/ -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 29 April 2022 Quarterly Activities and Cashflow Report Bionomics Limited (ASX:BNO, NASDAQ:BNOX), (“Bionomics” or “the Company”) a global, clinical stage bio
Quarterly Activities and Cashflow Report Bionomics Limited (ASX:BNO, NASDAQ:BNOX), ( Bionomics or the Company ) a global, clinical stage biopharmaceutical company, today released its Appendix 4C Quarterly Cashflow Report. Highlights during the quarter ended 31 March 2022 ( Quart
Read more →NEUPABN 53 075 582 740 BIONOMICS LIMITED ASX half-year information – 31 December 2021 Lodged with the ASX under Listing Rule 4.2A Contents Page Results for Announcement to the Market 2 Announcement 3 Half-year Report
ASX half-year information Lodged with the ASX under Listing Rule 4.2A Contents Page Results for Announcement to the Market 2 Announcement 3 Half-year Report 6 Half-year ended 31 December 2021 (Previous corresponding period: Half-year ended 31 December 2020) Results for annou
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 28 JANUARY 2022 Quarterly Activities and Cashflow Report Bionomics Limited (ASX:BNO, NASDAQ:BNOX), (“Bionomics” or “the Company”) a global, clinical stage b
Quarterly Activities and Cashflow Report Bionomics Limited (ASX:BNO, NASDAQ:BNOX), ( Bionomics or the Company ) a global, clinical stage biopharmaceutical company, today released its Appendix 4C - Quarterly Cashflow Report. Highlights during the quarter ended 31 December 2021 (
Read more →NEUPTO IMPROVE THE LIVES OF PATIENTS WITH SERIOUS CNS DISORDERS Corporate Presentation Nasdaq: BNOX ASX: BNO H.C. Wainwright BIOCONNECT Virtual Conference January 10 - 13, 2022 SAFE HARBOR STATEMENT 2 Factors Affecting Futur
Corporate Presentation Nasdaq: BNOX ASX: BNO H.C. Wainwright BIOCONNECT Virtual Conference January 10 - 13, 2022 SAFE HARBOR STATEMENT 2 Factors Affecting Future Performance This presentation may contain forward-looking statements within the meaning of the United States' Privat
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 04 January 2022 Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder Bionomics Limited (ASX:BNO, NASDAQ:BNOX) ( Bionomics or Company )
Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that it has initiated its Phase 2 clinical
Read more →NEUPABN 53 075 582 740 ASX ANNOUNCEMENT 31 December 2021 Resignation of Director Bionomics Limited ( Bionomics or Company ), a clinical-stage biopharmaceutical company, announced today the resignation of Mr Mitchell Kaye as
Resignation of Director Bionomics Limited (Bionomics or Company), a clinical-stage biopharmaceutical company, announced today the resignation of Mr Mitchell Kaye as a Non-Executive Director of the Board of Bionomics Limited effective 31 December 2021. Mr Kaye resigns under the
Read more →NEUPAppendix 3Y Change of Director s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
Director s Interest Notice Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and Introduced 30/09/01 Amended 01/01/11 Name of entity Bionomics
Read more →Competitive Position
How NEUP ranks across every disease it competes inCompetitive Position is a premium feature
See how NEUP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial